CD19 and CD21 expression levels and cytotoxicity of hBU12 -vcMMAE against ALL, CLL, and NHL tumor cell lines grown in culture
Tumor type / cell line . | CD21, copy no. . | CD19, copy no. . | IC50, nM hBU12-vcMMAE . | IC50, nM free MMAE . |
---|---|---|---|---|
ALL | ||||
Nalm-6 | 0 | 53773 | 4.0 ± 0.05 | 0.65 ± 0.07 |
RS4;11 | 0 | 38227 | 0.050 ± 0.007 | 0.080 ± 0.007 |
Transformed follicular lymphoma | ||||
DOHH2 | 0 | 40056 | 4.5 ± 0.7 | 0.200 ± 0.005 |
WSU-NHL | 0 | 36242 | 0.35 ± 0.07 | 0.200 ± 0.005 |
DLBCL | ||||
HT | 952 | 36834 | 0.20 ± 0.04 | 0.103 ± 0.002 |
RL | 0 | 32542 | > 300 | 0.25 ± 0.07 |
WSU-DLCL2 | 0 | 19924 | 51 ± 0.71 | 0.30 ± 0.01 |
SUDHL-6 | 0 | 13784 | 0.04 ± 0.01 | 0.136 ± 0.003 |
SUDHL-4 | 0 | 38932 | 99 ± 15 | 0.71 ± 0.07 |
Burkitt | ||||
CA46 | 2167 | 57240 | 1.4 ± 0.8 | 0.53 ± 0.09 |
Namalwa | 374 | 28629 | 45 ± 29 | 0.31 ± 0.10 |
Ramos | 2369 | 41016 | 0.60 ± 0.28 | 0.15 ± 0.01 |
Daudi | 25531 | 54074 | 30 ± 2 | 0.193 ± 0.007 |
Raji | 56660 | 78798 | 33.3 ± 7.1 | 0.43 ± 0.06 |
Large B-cell lymphoma | ||||
ARH-77 | 29537 | 54324 | 126 ± 31 | 0.63 ± 0.16 |
CLL | ||||
MEC-2 | 33246 | 67562 | > 300 | 2 ± 0.6 |
JVM3 | 17850 | 26321 | 42 ± 5 | 0.20 ± 0.07 |
T-cell leukemia | ||||
Jurkat: CD19− | > 300 | 0 | > 300 | 0.25 ± 0.04 |
Tumor type / cell line . | CD21, copy no. . | CD19, copy no. . | IC50, nM hBU12-vcMMAE . | IC50, nM free MMAE . |
---|---|---|---|---|
ALL | ||||
Nalm-6 | 0 | 53773 | 4.0 ± 0.05 | 0.65 ± 0.07 |
RS4;11 | 0 | 38227 | 0.050 ± 0.007 | 0.080 ± 0.007 |
Transformed follicular lymphoma | ||||
DOHH2 | 0 | 40056 | 4.5 ± 0.7 | 0.200 ± 0.005 |
WSU-NHL | 0 | 36242 | 0.35 ± 0.07 | 0.200 ± 0.005 |
DLBCL | ||||
HT | 952 | 36834 | 0.20 ± 0.04 | 0.103 ± 0.002 |
RL | 0 | 32542 | > 300 | 0.25 ± 0.07 |
WSU-DLCL2 | 0 | 19924 | 51 ± 0.71 | 0.30 ± 0.01 |
SUDHL-6 | 0 | 13784 | 0.04 ± 0.01 | 0.136 ± 0.003 |
SUDHL-4 | 0 | 38932 | 99 ± 15 | 0.71 ± 0.07 |
Burkitt | ||||
CA46 | 2167 | 57240 | 1.4 ± 0.8 | 0.53 ± 0.09 |
Namalwa | 374 | 28629 | 45 ± 29 | 0.31 ± 0.10 |
Ramos | 2369 | 41016 | 0.60 ± 0.28 | 0.15 ± 0.01 |
Daudi | 25531 | 54074 | 30 ± 2 | 0.193 ± 0.007 |
Raji | 56660 | 78798 | 33.3 ± 7.1 | 0.43 ± 0.06 |
Large B-cell lymphoma | ||||
ARH-77 | 29537 | 54324 | 126 ± 31 | 0.63 ± 0.16 |
CLL | ||||
MEC-2 | 33246 | 67562 | > 300 | 2 ± 0.6 |
JVM3 | 17850 | 26321 | 42 ± 5 | 0.20 ± 0.07 |
T-cell leukemia | ||||
Jurkat: CD19− | > 300 | 0 | > 300 | 0.25 ± 0.04 |
IC50 values were determined by incubation of the tumor cell lines for 96 hours to the hBU12-vcMMAE conjugate or MMAE, as indicated. Cell lines, in which less than 50% cytotoxicity was achieved at concentrations greater than or equal to 300 nM, were considered nonresponsive. Both unconjugated hBU12 and a control, nonbinding vcMMAE conjugate exhibited negligible antitumor activities against these cell lines. All values obtained for hBU12-vcMMAE are significantly different from control-vcMMAE compounds tested in the same assay (Student t test, data not shown). Jurkat cells were used as a CD19− control cell line. The absence of activity of hBU12-vcMMAE on these control cells suggested that the antitumor activity is immunologically specific. Data shown represent the mean plus or minus SD of three replicates from 2 independent experiments.